Agios Pharmaceuticals | Omløpsmidler



Current Assets Endring Dato
AbbVie USD 25.58B 2.2B 2024-12
Agios Pharmaceuticals USD 968.62M 3.02M 2025-03
Alnylam Pharmaceuticals USD 3.27B 27.03M 2025-03
Amgen USD 26.93B 2.1B 2025-03
Arrowhead Research USD 570.54M 124.93M 2024-12
Astellas Pharma JPY 1.2T 2.56B 2025-03
AstraZeneca USD 26.14B 312M 2025-03
Bayer EUR 34.44B 1.31B 2024-12
Biogen USD 7.63B 169.2M 2025-03
BioMarin Pharmaceutical USD 3.47B 235.48M 2025-03
Bristol-Myers Squibb USD 30.78B 1B 2025-03
Daiichi Sankyo JPY 1.91T 66.22B 2025-03
Eli Lilly USD 41.26B 8.52B 2025-03
Exelixis USD 1.47B 82.14M 2025-01
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 18.08B 1.09B 2025-03
Incyte USD 3.23B 7.24M 2025-03
Ionis Pharmaceuticals USD 2.42B 201.36M 2025-03
Merck USD 35.5B 3.28B 2025-03
Moderna USD 6.77B 1.33B 2025-03
Novartis USD 29.7B 1.56B 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 45.86B 4.5B 2025-03
Regeneron Pharmaceuticals USD 17.57B 9.64B 2025-03
Roche Holding CHF 40.04B 6.41B 2024-12
Sarepta Therapeutics USD 2.43B 640.93M 2025-03
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Agios Pharmaceuticals Omløpsmidler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.